Michael Cruse - 01 Sep 2022 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)

Role
Chief Operating Officer
Signature
/s/ Michael Cruse
Issuer symbol
OKUR
Transactions as of
01 Sep 2022
Net transactions value
+$25,448
Form type
4
Filing time
02 Sep 2022, 17:12:05 UTC
Previous filing
31 Aug 2022
Next filing
13 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPHM Common Stock Purchase $25,448 +7,500 +121% $3.39 13,697 01 Sep 2022 by Trust F1, F2
holding RPHM Common Stock 31,758 01 Sep 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average purchase price for the transaction was $3.393. The shares were purchased at a range of prices between $3.36 and $3.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F2 By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust.